Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PG4
- Development stage
- Phase 3
- Lead developer
- Pfizer
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
PG4 is a multivalent pneumococcal conjugate vaccine developed by Pfizer. It is designed to protect against pneumococcal disease, which is caused by the bacterium *Streptococcus pneumoniae*. The vaccine works by presenting specific bacterial polysaccharides, conjugated to a carrier protein, to the immune system, thereby stimulating the production of protective antibodies. Clinical trials are evaluating its safety, tolerability, and immunogenicity in various populations, including adults, toddlers, and infants.
- Other names
- multivalent pneumococcal conjugate vaccinePfizer 25-valent pneumococcal conjugate vaccinePfizer25-valent pneumococcal conjugate vaccinePfizer-25-valent pneumococcal conjugate vaccine
Beyond the preview
Go deeper on PG4.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PG4.